Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Patent
1998-04-22
2000-02-22
Rotman, Alan L.
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C07D40104
Patent
active
060281960
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
Growth hormone, which is secreted from the pituitary, stimulates growth of all tissues of the body that are capable of growing. In addition, growth hormone is known to have the following basic effects on the metabolic processes of the body: (1) Increased rate of protein synthesis in all cells of the body; (2) Decreased rate of carbohydrate utilization in cells of the body; (3) Increased mobilization of free fatty acids and use of fatty acids for energy. A deficiency in growth hormone secretion can result in various medical disorders, such as dwarfism.
Various ways are known to release growth hormone. For example, chemicals such as arginine, L-3,4-dihydroxyphenylalanine (L-DOPA), glucagon, vasopressin, and insulin induced hypoglycemia, as well as activities such as sleep and exercise, indirectly cause growth hormone to be released from the pituitary by acting in some fashion on the hypothalamus perhaps either to decrease somatostatin secretion or to increase the secretion of the known secretagogue growth hormone releasing factor (GRF) or an unknown endogenous growth hormone-releasing hormone or all of these.
In cases where increased levels of growth hormone were desired, the problem was generally solved by providing exogenous growth hormone or by administering GRF or a peptidal compound which stimulated growth hormone production and/or release. In either case the peptidyl nature of the compound necessitated that it be administered by injection. Initially the source of growth hormone was the extraction of the pituitary glands of cadavers. This resulted in a very expensive product and carried with it the risk that a disease associated with the source of the pituitary gland could be transmitted to the recipient of the growth hormone. Recombinant growth hormone has become available which, while no longer carrying any risk of disease transmission, is still a very expensive product which must be given by injection or by a nasal spray. Other compounds have been developed which stimulate the release of endogenous growth hormone.
In particular, certain spiro compounds are disclosed in PCT Patent Publication WO 94/13696 and Proc. Natl. Acad. Sci. USA, 92, 7001-7005 (July 1995) as being non-peptidal growth hormone secretagogues. These compounds have the ability to stimulate the release of natural or endogenous growth hormone and thus may be used to treat conditions which require the stimulation of growth hormone production or secretion such as in humans with a deficiency of natural growth hormone or in animals used for food or wool production where the stimulation of growth hormone will result in a larger, more productive animal.
Among the preferred compounds disclosed therein is spiro[3H-indole-3,4'-piperdin]-1'-yl)carbonyl]-2-(phenylmethyl-oxy)ethyl]- 2-amino-2-methylpropanamide which has the structure: ##STR2##
PCT Patent Publication WO 94/13696 discloses methods for preparing this compound (see Examples 18, 19 and 55). However, the synthesis of the compound was accomplished by using the very expensive amino acid coupling agent EDC ($1100/kg); the use of numerous equivalents of trifluoroacetic acid as the catalyst for the BOC group deprotections; extensive chromatographic purifications; and resulted in "gumming" of the final product.
The advantages of the present invention include: a 6-step high yielding non-isolation process providing material of .gtoreq.99.9% purity; decreased expense through the use of DCC [$40/kg] instead of EDC [$1100/kg]; diminished environmental impact through the use of methanesulfonic acid instead of trifluoroacetic acid as the catalyst (as well as lesser equivalents of catalyst) in the deprotections; and ease of isolation of the final product.
SUMMARY OF THE INVENTION
The instant invention is directed to a process for the preparation of the compound N-[1(R)-[(1,2-dihydro-1-methanesulfonyl-spiro[3H-indole-3,4'-piperdin]-1'- yl)carbonyl]-2-(phenylmethyl-oxy)ethyl]-2-amino-2-methyl-propanamide which has the structure: ##STR3## and salts thereof, in particular,
REFERENCES:
patent: 5536716 (1996-07-01), Chen et al.
patent: 5723616 (1998-03-01), Houghton et al.
patent: 5767124 (1998-06-01), Draper et al.
A.A. Patchet, et al, Proc. Natl. Acad. Sci. USA, vol. 92, pp. 7001-7005 (Jul. 1995).
Ioannis Houpis, et al, "Synthesis of the Orally Active Nonpeptidal Growth Hormone Secretagogue, MK-677", Presentation at Gordon Research Conference, New Hampton, NH (Jul. 14, 1996).
Houghton Peter
Houpis Ioannis
Lynch Joseph
Molina Audrey
Volante Ralph
Aulakh Charanjit S.
Merck & Co. , Inc.
Rose David L.
Rotman Alan L.
Thies J. Eric
LandOfFree
Process for the preparation of a growth hormone secretagogue does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for the preparation of a growth hormone secretagogue, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the preparation of a growth hormone secretagogue will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-521751